Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of HM15912 in Subjects with Renal Impairment
NCT05711381Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of sonefpeglutide in short bowel syndrome (SBS) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Serum Concentration and Area Under the Concentration-time Curve From Extrapolated to Infinity. Started Dec 2022; status: completed.
02
Drugs
sonefpeglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT05711381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711381.